World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
58
Citations
17029
World Ranking
12965
National Ranking
5525

Overview

Michael D. Hogarty is affiliated with the Children's Hospital of Philadelphia in the United States. Their research primarily focuses on various aspects of neuroblastoma, including risk classification, genetic alterations, and potential therapeutics.

The scientist's recent publications include:

  • "Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group," 2021, Journal of Clinical Oncology
  • "Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations," 2020, Nature Communications
  • "Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma," 2021, Nature Communications
  • "MYCN amplification and ATRX mutations are incompatible in neuroblastoma," 2020, Nature Communications
  • "Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project," 2020, Journal of Clinical Oncology

Frequent co-authors collaborating with Michael D. Hogarty include:

  • Arlene Naranjo
  • Julie R. Park
  • John M. Maris
  • Meredith S. Irwin
  • Wendy B. London

The most common venues for their publications are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Pediatric Blood & Cancer
  • Cancer Research
  • Nature Communications

Michael D. Hogarty's work primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their subfields of study include:

  • Neurology
  • Molecular Biology
  • Cancer Research
  • Oncology
  • Immunology

Key topics covered in their research are:

  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Cancer therapeutics and mechanisms
  • Histiocytic Disorders and Treatments
  • Lung Cancer Research Studies
  • Virus-based gene therapy research
  • Neurofibromatosis and Schwannoma Cases

Best Publications

  • Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Chetan Bettegowda;Chetan Bettegowda;Mark Sausen;Rebecca J. Leary;Isaac Kinde

  • The genetic landscape of high-risk neuroblastoma

    Trevor J Pugh;Olena Morozova;Edward F Attiyeh;Edward F Attiyeh;Shahab Asgharzadeh;Shahab Asgharzadeh

  • Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

    Thomas F Eleveld;Derek A Oldridge;Virginie Bernard;Jan Koster

  • Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.

    Mark Sausen;Rebecca J Leary;Siân Jones;Siân Jones;Jian Wu;Jian Wu

  • ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation

    Guoliang Qing;Bo Li;Annette Vu;Nicolas Skuli;Nicolas Skuli

  • Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

    Julie R. Park;Rochelle Bagatell;Wendy B. London;John M. Maris

  • ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

    Scott C. Bresler;Daniel A. Weiser;Daniel A. Weiser;Peter J. Huwe;Jin H. Park

  • Biology and genetics of human neuroblastomas.

    Garrett M. Brodeur;John M. Maris;Darrell J. Yamashiro;Michael D. Hogarty

  • Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.

    Chun Guo;Peter S White;Matthew J Weiss;Michael D Hogarty

  • Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.

    Julie R. Park;Julie R. Park;Susan G. Kreissman;Wendy B. London;Arlene Naranjo

  • Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.

    Meredith S Irwin;Arlene Naranjo;Fan F Zhang;Susan L Cohn

  • ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

    Michael D. Hogarty;Murray D. Norris;Kimberly Davis;Xueyuan Liu

  • MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.

    Michael A. Grotzer;Michael D. Hogarty;Anna J. Janss;Xueyuan Liu

  • Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.

    Peter S White;Peter S White;Patricia M Thompson;Takahiro Gotoh;Erin R Okawa

  • Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

    Joëlle Vermeulen;Katleen De Preter;Arlene Naranjo;Liesbeth Vercruysse

  • Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

    John M. Maris;Matthew J. Weiss;Chun Guo;Robert B. Gerbing

  • Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass Lesions

    Nicholas R. Mahoney;Grant T. Liu;Grant T. Liu;Sheryl J. Menacker;Martin C. Wilson

  • Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.

    X Liu;P Mazanek;V Dam;Q Wang

  • Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

    L L Wang;R Teshiba;N Ikegaki;X X Tang

  • Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

    Kevin Campbell;Julie M. Gastier-Foster;Julie M. Gastier-Foster;Meegan Mann;Arlene H. Naranjo

Frequent Co-Authors

John M. Maris
John M. Maris Children's Hospital of Philadelphia
Wendy B. London
Wendy B. London Harvard University
Julie M. Gastier-Foster
Julie M. Gastier-Foster Baylor College of Medicine
Garrett M. Brodeur
Garrett M. Brodeur Children's Hospital of Philadelphia
Susan L. Cohn
Susan L. Cohn University of Chicago
Robert C. Seeger
Robert C. Seeger Children's Hospital of Los Angeles
Peter White
Peter White Nationwide Children's Hospital
Katherine K. Matthay
Katherine K. Matthay University of California, San Francisco
Hiroyuki Shimada
Hiroyuki Shimada Stanford University
Yael P. Mosse
Yael P. Mosse Children's Hospital of Philadelphia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Biology and Biochemistry opens the door to a wide variety of online degree programs and career opportunities in health, fitness, and medical fields. Professionals with a biology background may explore specialties like exercise science or kinesiology, which blend biological principles with practical applications in health and sports. For those interested in this direction, consider programs such as the exercise science online degree or the best online kinesiology degree.

Advanced biology education, especially at the graduate level, can also lead to high-demand roles in healthcare. Fast-track online options like a 1 year pmhnp program online or a post masters fnp programs help experienced clinicians specialize further. These pathways enable biology and biochemistry graduates to contribute in clinical, wellness, and mental health settings with specialized, in-demand skills.

Exploring these related online degrees can maximize your career flexibility and allow you to tailor your pathway according to your interests within the life sciences field.

Best Scientists Citing Michael D. Hogarty

Trending Scientists

Recently Published Articles